Your Good Partner in Biology Research

重组蛋白

产品名称 货号 规格
Recombinant Human Orexin receptor type 2 (HCRTR2), partial CSB-YP010232HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Rat Sortilin (Sort1), partial CSB-YP022412RA 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), partial CSB-YP012906HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Protein phosphatase 1 regulatory subunit 15A (PPP1R15A), partial CSB-YP018528HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4), partial CSB-YP005164HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Potassium channel subfamily K member 2 (KCNK2), partial CSB-YP012070HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Sodium-dependent phosphate transport protein 2B (SLC34A2), partial CSB-YP021581HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Breast carcinoma-amplified sequence 1 (BCAS1) CSB-YP002596HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Mouse Roundabout homolog 1 (Robo1), partial CSB-YP020054MO 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Lymphocyte antigen 6H (LY6H) CSB-YP013249HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Poly (A)-specific ribonuclease PARN (PARN) CSB-YP017456HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Pig Coagulation factor XII (F12), partial CSB-YP007918PI 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Prostate stem cell antigen (PSCA) CSB-YP018840HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Mouse Legumain (Lgmn) CSB-YP012903MO 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Bovine Metalloproteinase inhibitor 4 (TIMP4) CSB-YP023563BO 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), partial CSB-RP000254h 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human 60S ribosomal protein L11 (RPL11), partial CSB-RP000654h 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Protein disulfide-isomerase (P4HB), partial CSB-RP002544h 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human 60S ribosomal protein L8 (RPL8), partial CSB-RP005954h 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Tyrosine--tRNA ligase, Cytoplasmic domain (YARS1) CSB-EP026245HU 1mg(1mg*1 or 500ug*2)/100ug/20ug

有用资源

什么是重组蛋白?

重组蛋白是一种可操纵的蛋白质形式,可以通过多种方式产生大量蛋白质、修改基因序列和制造有用的商业产品。重组蛋白的技术资源在重组蛋白的开发过程中,除了表达系统之外,还面临着一系列令人困惑的选择,如表达载体的选择、表达蛋白的长度(全长或部分)、是否带标签等。在生产重组蛋白时,你必须做出很多决定。如果你选择的明智,你将获得高质量的重组蛋白,后续的实验更有可能成功。但是如果你做了错误的决定,你可能得不到你所需要的重组蛋白或者重组蛋白的质量和纯度不符合要求。在这里,来自CUSABIO的蛋白表达工程师根据他们开发重组蛋白的经验总结出了几个有用的提示,可以帮助你做出明智的决策。

第一条:重组蛋白的生产,在这篇文章中,我们旨在阐明重组蛋白的定义以及如何生产重组蛋白。

第二条:如何选择合适的表达载体?

表达载体是一种DNA分子,它携带特定的基因进入宿主细胞,并利用细胞的蛋白质合成机制来产生由该基因编码的蛋白质。表达载体可使外源基因在宿主细胞中高效表达,经过多年的发展,表达载体已成为一种成熟而受欢迎的生物技术。在重组蛋白生产过程中是一种基本成分。正如标题所示,本文主要总结了几个有用的技巧来选择合适的表达载体。

第三条:如何表达具有生物活性的蛋白质?

根据重组蛋白的不同应用,对其生物活性有不同的要求。但是我们如何确保蛋白质的产生具有生物活性呢?本文将围绕这个主题,并提供一些解决方案。除了以上文章,我们还收集了一些重组蛋白的常见问题。您可以单击以下链接查看。/technology-91.html。此外,我们还为我们的客户提供重组蛋白表达服务,您可以点击这里获取更多信息。注:如果您对CUSABIO的蛋白质有任何疑问,涉及到蛋白质的价格、交货、质量等,您可以点击橙色按钮为我们在线留言。

引用资料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>